ImmuPharma (LON:IMM) Trading Down 10% - Here's What Happened

Key Points

• ImmuPharma plc experienced a significant drop of 10% in its stock price, trading as low as GBX 10.51 ($0.14) during mid-day trading.
• The company reported a negative earnings per share (EPS) of GBX (0.38) for its last quarter, with analysts forecasting an EPS of -339.0000022 for the current fiscal year.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program aimed at treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares dropped 10% during mid-day trading on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares were traded during mid-day trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Down 10.0%

The business has a 50-day simple moving average of GBX 4.46 and a 200-day simple moving average of GBX 3.33. The company has a market cap of £56.23 million, a PE ratio of -1,264.38 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.